EC suspends research and innovation cooperation with Russia

4 March 2022
european_commission_large

Following the Russian invasion against Ukraine and in solidarity with the people of Ukraine, the European Commission said today it has decided to suspend the cooperation with Russian entities in research, science and innovation. The Commission will not conclude any new contracts nor any new agreements with Russian organizations under the Horizon Europe program.

Furthermore, the Commission is suspending payments to Russian entities under existing contracts. All ongoing projects, in which Russian research organizations are participating, are being reviewed – both under Horizon Europe and Horizon 2020, the previous EU program for research and innovation.

Margrethe Vestager, executive vice president for a Europe fit for the Digital Age, said: “EU research cooperation is based on the respect for the freedoms and rights that underpin excellence and innovation. Russia's heinous military aggression against Ukraine is an attack against those same values. It is therefore time to put an end to our research cooperation with Russia.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical